I. Ostrovnaya

发表

Radiogenomics of clear cell renal cell carcinoma: associations between CT imaging features and mutations.

H. Hricak, P. Russo, O. Akin, 2013, Radiology.

Comprehensive molecular characterization of clear cell renal cell carcinoma

Steven J. M. Jones, Benjamin J. Raphael, Evan O. Paull, 2013, Nature.

Genome Sequencing Identifies a Basis for Everolimus Sensitivity

C. Sander, N. Socci, B. Taylor, 2012, Science.

Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer.

C. Sander, B. Taylor, N. Schultz, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma.

S. Gabriel, G. Getz, P. Kantoff, 2014, Cancer discovery.

A Landscape of Metabolic Variation across Tumor Types.

C. Sander, B. A. Aksoy, A. Hakimi, 2018, Cell systems.

Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators BAP1 and SETD2: A Report by MSKCC and the KIRC TCGA Research Network

C. Sander, N. Schultz, B. Reva, 2013, Clinical Cancer Research.

Erratum to: Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures

Ludmila V. Danilova, C. Sander, E. V. Van Allen, 2016, Genome Biology.

Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures

Ludmila V. Danilova, C. Sander, E. V. Van Allen, 2016, Genome Biology.

The spinal distribution of metastatic renal cell carcinoma: Support for locoregional rather than arterial hematogenous mode of early bony dissemination.

M. Bilsky, P. Russo, A. Hakimi, 2021, Urologic oncology.

ESTIMATING THE PROPORTION OF TRUE NULL HYPOTHESES UNDER DEPENDENCE

Irina Ostrovnaya, Dan L. Nicolae, D. Nicolae, 2012 .

Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: Results of a phase I study

I. Ostrovnaya, K. Hsu, D. Goldman, 2018, Oncoimmunology.

Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin

I. Ostrovnaya, N. Cheung, D. Kuk, 2015, Oncotarget.

Key role for myeloid cells: Phase II results of anti‐GD2 antibody 3F8 plus granulocyte‐macrophage colony‐stimulating factor for chemoresistant osteomedullary neuroblastoma

I. Ostrovnaya, N. Cheung, D. Kuk, 2014, International journal of cancer.

A High-Content Screen for C/EBPα Expression Identifies Novel Therapeutic Agents in Dedifferentiated Liposarcoma

I. Ostrovnaya, S. Singer, David Shum, 2021, Clinical Cancer Research.

The high incidence of vascular thromboembolic events in patients with metastatic or unresectable urothelial cancer treated with platinum chemotherapy agents

I. Ostrovnaya, D. Bajorin, E. Zabor, 2016, Cancer.

Timing of blood transfusion and oncologic outcomes in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma

I. Ostrovnaya, J. Coleman, B. Bochner, 2018, World Journal of Urology.

The predictive role of preoperative and postoperative neutrophil-lymphocyte ratio in sarcomatoid renal cell carcinoma.

P. Russo, A. Hakimi, I. Ostrovnaya, 2019, Urologic oncology.

Sunitinib in urothelial cancer: clinical, pharmacokinetic, and immunohistochemical study of predictors of response.

I. Ostrovnaya, M. Milowsky, H. Al-Ahmadie, 2011, European urology.

Neoadjuvant Gemcitabine-Cisplatin Plus Radical Cystectomy-Pelvic Lymph Node Dissection for Muscle-invasive Bladder Cancer: A 12-year Experience.

P. Russo, I. Ostrovnaya, G. Iyer, 2020, Clinical genitourinary cancer.

The landscape of T cell infiltration in human cancer and its association with antigen presenting gene expression

C. Sander, N. Weinhold, William Lee, 2015, bioRxiv.

A pediatric trial of radiation/cetuximab followed by irinotecan/cetuximab in newly diagnosed diffuse pontine gliomas and high‐grade astrocytomas: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study

T. MacDonald, I. Ostrovnaya, M. Kieran, 2017, Pediatric blood & cancer.

Synchronous Hepatic Metastases from Colon Cancer: Changing Treatment Strategies and Results of Surgical Intervention

I. Ostrovnaya, M. Gonen, M. D'Angelica, 2009, Annals of Surgical Oncology.

A phase 2 trial of buparlisib in patients with platinum‐resistant metastatic urothelial carcinoma

M. Berger, E. V. Van Allen, I. Ostrovnaya, 2020, Cancer.

Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults

I. Ostrovnaya, N. Cheung, Jessie W Gu, 2016, Pediatric blood & cancer.

Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer.

I. Ostrovnaya, M. Milowsky, D. Bajorin, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of the clonal origin of multiple primary melanomas using molecular profiling.

C. Begg, I. Ostrovnaya, R. Scolyer, 2009, The Journal of investigative dermatology.

Genomic and Mutational Profiling to Assess Clonal Relationships Between Multiple Non–Small Cell Lung Cancers

N. Girard, M. Ladanyi, C. Begg, 2009, Clinical Cancer Research.

Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission.

I. Ostrovnaya, N. Cheung, B. Kushner, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated With Neoadjuvant Chemotherapy.

V. Reuter, I. Ostrovnaya, B. Weigelt, 2022, Clinical genitourinary cancer.

An EM algorithm to improve the estimation of the probability of clonal relatedness of pairs of tumors in cancer patients

Irina Ostrovnaya, Colin B Begg, Venkatraman E Seshan, 2019, BMC Bioinformatics.

Assessment of Organ Dosimetry for Planning Repeat Treatments of High-Dose 131I-MIBG Therapy: 123I-MIBG Versus Posttherapy 131I-MIBG Imaging

I. Ostrovnaya, J. Carrasquillo, P. Zanzonico, 2017, Clinical nuclear medicine.

The spinal distribution of metastatic renal cell carcinoma: Support for locoregional rather than arterial hematogenous mode of early bony dissemination.

M. Bilsky, P. Russo, I. Ostrovnaya, 2020, Urologic oncology.

The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience.

J. Chaim, I. Ostrovnaya, M. Voss, 2015, The oncologist.

Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma.

C. Antonescu, I. Ostrovnaya, N. Katabi, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The high incidence of vascular thromboembolic events (VTE) in advanced urothelial cancer (UC) patients (pts) treated with carboplatin (Cb): Analysis of treatment with gemcitabine (G)/cb (GCb), gcb/bevacizumab (GCbBev), or gemcitabine/cisplatin (GCis).

I. Ostrovnaya, D. Bajorin, E. Zabor, 2014 .

Chromophobe Renal Cell Carcinoma: Results From a Large Single-Institution Series.

P. Russo, V. Reuter, A. Hakimi, 2019, Clinical genitourinary cancer.

Chromophobe renal cell carcinoma: results from a large single-institutional series

P. Russo, V. Reuter, I. Ostrovnaya, 2019 .

Pretreatment Eosinophil Counts in Patients With Advanced or Metastatic Urothelial Carcinoma Treated With Anti-PD-1/PD-L1 Checkpoint Inhibitors

I. Ostrovnaya, G. Iyer, D. Bajorin, 2021, Journal of immunotherapy.

Osteochondroma in long‐term survivors of high‐risk neuroblastoma

I. Ostrovnaya, N. Cheung, D. Kuk, 2015, Cancer.

FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation

Mauro A. A. Castro, A. Lenis, N. Socci, 2022, Nature Communications.

Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype.

A. Lenis, V. Reuter, I. Ostrovnaya, 2022, JCO precision oncology.

Comparison of Properties of Tests for Assessing Tumor Clonality

V. Seshan, C. Begg, I. Ostrovnaya, 2008, Biometrics.

Bone marrow minimal residual disease was an early response marker and a consistent independent predictor of survival after anti-GD2 immunotherapy.

I. Ostrovnaya, D. Kuk, N. Cheung, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genomic heterogeneity as a barrier to precision oncology in urothelial cancer

A. Lenis, M. Berger, I. Ostrovnaya, 2022, Cell reports.

Final results of a phase II study of everolimus (RAD001) in metastatic transitional cell carcinoma (TCC) of the urothelium.

I. Ostrovnaya, M. Milowsky, H. Al-Ahmadie, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Next‐generation sequencing of urine specimens: A novel platform for genomic analysis in patients with non–muscle‐invasive urothelial carcinoma treated with bacille Calmette‐Guérin

M. Berger, I. Ostrovnaya, Sasinya N. Scott, 2017, Cancer cytopathology.

Identifying prognostic pairwise relationships among bacterial species in microbiome studies

I. Ostrovnaya, S. Devlin, Axel Martin, 2021, PLoS Comput. Biol..

Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors.

V. Vacic, N. Schultz, M. Berger, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Erratum to: Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures

Ludmila V. Danilova, C. Sander, E. V. Van Allen, 2017, Genome Biology.

A classification model for distinguishing copy number variants from cancer-related alterations

Adam B. Olshen, Irina Ostrovnaya, Gouri Nanjangud, 2010, BMC Bioinformatics.

NEXT GENERATION SEQUENCING OF NON‐MUSCLE INVASIVE BLADDER CANCER REVEALS POTENTIAL BIOMARKERS AND RATIONAL THERAPEUTIC TARGETS: PD48‐11

N. Schultz, M. Berger, I. Ostrovnaya, 2017, European urology.

Genomic characterization of response to chemoradiation in urothelial bladder cancer

M. Berger, M. Zelefsky, I. Ostrovnaya, 2016, Cancer.

Genomic Characterization of Upper Tract Urothelial Carcinoma.

N. Schultz, M. Berger, V. Reuter, 2015, European urology.

Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder.

N. Schultz, M. Berger, V. Reuter, 2015, European urology.

Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenografts

Jianjiong Gao, A. Hakimi, I. Ostrovnaya, 2020, Nature Communications.

B. Taylor, M. Berger, I. Ostrovnaya, 2018, Clinical Cancer Research.

Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers.

M. Berger, J. Wolchok, J. Chaim, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma

M. Berger, I. Ostrovnaya, H. Al-Ahmadie, 2017, Clinical Cancer Research.

Phase II study of everolimus in metastatic urothelial cancer

I. Ostrovnaya, G. Iyer, M. Milowsky, 2013, BJU international.

Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome

P. Raman, I. Ostrovnaya, J. Maris, 2016, PLoS genetics.

Recurrent pre‐existing and acquired DNA copy number alterations, including focal TERT gains, in neuroblastoma central nervous system metastases

Irina Ostrovnaya, I. Ostrovnaya, S. Tickoo, 2013, Genes, chromosomes & cancer.

Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-GD2 immunotherapy and isotretinoin: a prospective Phase II study

I. Ostrovnaya, D. Kuk, B. Kushner, 2015, Oncoimmunology.

Reply to L. Moreno et al.

I. Ostrovnaya, B. Kushner, N. Cheung, 2013, Journal of Clinical Oncology.

Contralateral breast cancers: Independent cancers or metastases?

V. Seshan, C. Begg, J. Reis-Filho, 2018, International journal of cancer.

V. Seshan, C. Begg, I. Ostrovnaya, 2012, Breast Cancer Research.

Clonal relationships between lobular carcinoma in situ and other breast malignancies

V. Seshan, C. Begg, I. Ostrovnaya, 2016, Breast Cancer Research.

Aminopeptidase activities as prospective urinary biomarkers for bladder cancer

I. Ostrovnaya, B. Bochner, H. Lilja, 2014, Proteomics. Clinical applications.

Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer

B. Taylor, A. Viale, M. Berger, 2016, Nature Genetics.

Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma.

J. Cheville, V. Seshan, E. Papaemmanuil, 2017, JCI insight.

Comprehensive molecular characterization of clear cell renal cell carcinoma

Steven J. M. Jones, Eric S. Lander, Benjamin J. Raphael, 2013, Nature.

Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study.

R. Motzer, P. Russo, I. Ostrovnaya, 2019, The Lancet. Oncology.

Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma

A. Jacobsen, K. Offit, R. Klein, 2016, Cancer.

The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling

R. Motzer, P. Russo, A. Hakimi, 2014, Cancer medicine.

Impact of recurrent copy number alterations and cancer gene mutations on the predictive accuracy of prognostic models in clear cell renal cell carcinoma.

G. Ciriello, R. Motzer, P. Russo, 2014, The Journal of urology.

Combining integrated genomics and functional genomics to dissect the biology of a cancer‐associated, aberrant transcription factor, the ASPSCR1–TFE3 fusion oncoprotein

C. Leslie, A. Olshen, M. Ladanyi, 2013, The Journal of pathology.

A metastasis or a second independent cancer? Evaluating the clonal origin of tumors using array copy number data

Irina Ostrovnaya, Irene Orlow, D. Albertson, 2010, Statistics in medicine.

Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial

I. Ostrovnaya, G. Iyer, H. Al-Ahmadie, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer.

C. Bourque, M. Berger, I. Ostrovnaya, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer.

K. Offit, I. Ostrovnaya, E. Plimack, 2016, Clinical genitourinary cancer.

Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial.

R. Motzer, V. Reuter, A. Hakimi, 2019, Cancer discovery.

A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response

R. Motzer, I. Ostrovnaya, M. Voss, 2020, Nature Communications.

V. Seshan, C. Begg, I. Ostrovnaya, 2012, Breast Cancer Research.

Clonality: an R package for testing clonal relatedness of two tumors from the same patient based on their genomic profiles

Adam B. Olshen, Colin B. Begg, Irina Ostrovnaya, 2011, Bioinform..

Testing clonal relatedness of two tumors from the same patient based on their mutational profiles: update of the Clonality R package

Irina Ostrovnaya, Colin B Begg, Venkatraman E Seshan, 2019, Bioinform..

Estimating the probability of clonal relatedness of pairs of tumors in cancer patients

V. Seshan, C. Begg, I. Ostrovnaya, 2018, Biometrics.

USING SOMATIC MUTATION DATA TO TEST TUMORS FOR CLONAL RELATEDNESS.

V. Seshan, C. Begg, I. Ostrovnaya, 2015, The annals of applied statistics.

Testing tumors from different anatomic sites for clonal relatedness using somatic mutation data

V. Seshan, C. Begg, I. Ostrovnaya, 2020, Biometrics.

Testing Clonal Relatedness of Tumors Using Array Comparative Genomic Hybridization: A Statistical Challenge

C. Begg, I. Ostrovnaya, 2010, Clinical Cancer Research.

Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Non–Muscle-Invasive Bladder Cancer

M. Berger, K. Offit, I. Ostrovnaya, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma.

I. Ostrovnaya, G. Iyer, M. Milowsky, 2020, European urology.

Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial Carcinoma.

M. Berger, V. Reuter, I. Ostrovnaya, 2017, European urology focus.

Germline single nucleotide polymorphisms associated with response of urothelial carcinoma to platinum-based therapy: the role of the host.

K. Offit, I. Ostrovnaya, G. Iyer, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II trial of durvalumab and tremelimumab in metastatic, non‐urothelial carcinoma of the urinary tract

J. Chaim, I. Ostrovnaya, G. Iyer, 2020, Cancer medicine.

Marker lesion study of oral FGFR inhibitor BGJ398 in patients with FGFR3-altered intermediate-risk nonmuscle-invasive bladder cancer.

I. Ostrovnaya, G. Iyer, B. Bochner, 2020 .

Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy.

I. Ostrovnaya, M. Milowsky, D. Bajorin, 2013, Journal of the National Cancer Institute.

Prospective Evaluation of Unprocessed Core Needle Biopsy DNA and RNA Yield from Lung, Liver, and Kidney Tumors: Implications for Cancer Genomics

E. Ziv, I. Ostrovnaya, J. Hsieh, 2018, Analytical cellular pathology.

Assessment of SLX4 Mutations in Hereditary Breast Cancers

K. Offit, I. Ostrovnaya, T. Kirchhoff, 2013, PloS one.

A Metastasis or a Second Independent Cancer ? Evaluating the Clonal Origin of Tumors Using Array-CGH Data

D. Albertson, A. Olshen, V. Seshan, 2017 .

Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures

E. V. Van Allen, N. Weinhold, William Lee, 2016, Genome Biology.

Integrin beta 3 genotype influences asthma and allergy phenotypes in the first 6 years of life.

D. Nicolae, C. Ober, I. Ostrovnaya, 2007, The Journal of allergy and clinical immunology.

Phase I Study of Everolimus in Combination with Gemcitabine and Split-Dose Cisplatin in Advanced Urothelial Carcinoma

I. Ostrovnaya, M. Voss, M. Milowsky, 2016, Bladder cancer.

Nonenhancing Component of Clear Cell Renal Cell Carcinoma on Computed Tomography Correlates With Tumor Necrosis and Stage and Serves as a Size-Independent Prognostic Biomarker.

L. Schwartz, Binsheng Zhao, O. Akin, 2019, Journal of computer assisted tomography.

Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma.

M. Berger, V. Reuter, I. Ostrovnaya, 2016, The Journal of urology.

Local recurrences at the anastomotic area are clonally related to the primary tumor in sporadic colorectal carcinoma

Johannes G. Reiter, M. Berger, C. Iacobuzio-Donahue, 2017, Oncotarget.

Evaluating the association of multiple single nucleotide polymorphisms with response to gemcitabine and platinum combination chemotherapy in urothelial carcinoma of the bladder .

K. Offit, I. Ostrovnaya, D. Bajorin, 2017, International journal of clinical pharmacology and therapeutics.

NSD1 analysis for Sotos syndrome: Insights and perspectives from the clinical laboratory

E. Anderes, I. Ostrovnaya, C. Martin, 2005, Genetics in Medicine.

Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma

V. Reuter, I. Ostrovnaya, S. Tickoo, 2021, British Journal of Cancer.

PTEN Expression, Not Mutation Status in TSC1, TSC2, or mTOR, Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial

V. Seshan, R. Motzer, A. Hakimi, 2018, Clinical Cancer Research.

Novel Genetic Subtypes of Urothelial Carcinoma With Differential Outcomes on Immune Checkpoint Blockade

V. Seshan, Chen Zhao, I. Ostrovnaya, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

DNA damage repair and response (DDR) gene alterations (alt) and response to PD1/PDL1 blockade in platinum-treated metastatic urothelial carcinoma (mUC).

J. Wolchok, J. Chaim, I. Ostrovnaya, 2017 .

Correlation of DNA damage response (DDR) gene alterations with response to neoadjuvant (neo) dose-dense gemcitabine and cisplatin (ddGC) in urothelial carcinoma (UC).

I. Ostrovnaya, G. Iyer, M. Milowsky, 2016 .

The impact of PBRM1 mutations on overall survival in greater than 2,100 patients treated with immune checkpoint blockade (ICB).

R. Motzer, A. Hakimi, I. Ostrovnaya, 2019, Journal of Clinical Oncology.

Association of somatic ERCC2 mutations with cisplatin sensitivity in muscle-invasive urothelial carcinoma.

S. Gabriel, G. Getz, P. Kantoff, 2014 .

Incidence and clinical outcomes of HER2-altered bladder cancer (BC) patients (pts).

I. Ostrovnaya, A. Niederhausern, G. Iyer, 2022, Journal of Clinical Oncology.

Somatic mutations as preoperative predictors of metastases in patients with localized clear cell renal cell carcinoma - An exploratory analysis.

M. Kattan, P. Russo, O. Akin, 2021, Urologic oncology.

Preoperative nomogram predicting 12-year probability of metastatic renal cancer - evaluation in a contemporary cohort.

M. Kattan, P. Russo, O. Akin, 2020, Urologic oncology.

Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy.

N. Socci, B. Taylor, N. Schultz, 2014, Cancer discovery.

Genetic Ancestry Correlates with Somatic Differences in a Real-World Clinical Cancer Sequencing Cohort.

N. Schultz, M. Ladanyi, M. Berger, 2022, Cancer discovery.

Phase II trial of neoadjuvant gemcitabine (G) and cisplatin (C) with sunitinib in patients (pts) with muscle-invasive bladder cancer (MIBC).

I. Ostrovnaya, G. Iyer, M. Milowsky, 2012 .

Gemcitabine-cisplatin (GC) plus radical cystectomy-pelvic lymph node dissection (RC-PLND) for patients (pts) with muscle-invasive bladder cancer (MIBC): Assessing impacts of neoadjuvant chemotherapy (NAC) and the PLND.

I. Ostrovnaya, B. Bochner, D. Bajorin, 2014 .

Alterations in the PI3K/Akt signaling pathway and association with outcome in invasive high-grade urothelial cancer (UC).

I. Ostrovnaya, G. Iyer, M. Milowsky, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A nomogram predicting survival of patients (pts) with metastatic or unresectable urothelial cancer (UC) treated with cisplatin-based chemotherapy

I. Ostrovnaya, M. Milowsky, D. Bajorin, 2007 .

A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear Cell Renal Cell Carcinoma.

S. Lowe, R. Motzer, P. Russo, 2022, Cancer discovery.

Phase II trial of gemcitabine, carboplatin, and bevacizumab (Bev) in patients (pts) with advanced/metastatic urothelial carcinoma (UC).

I. Ostrovnaya, M. Milowsky, D. Bajorin, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinicopathologic features associated with survival after cytoreductive nephrectomy for nonclear cell renal cell carcinoma.

R. Motzer, P. Russo, I. Ostrovnaya, 2019, Urologic oncology.

Deep MicroRNA sequencing reveals downregulation of miR‐29a in neuroblastoma central nervous system metastasis

T. Tuschl, I. Ostrovnaya, T. Farazi, 2014, Genes, chromosomes & cancer.

Gene-environment interaction effects on the development of immune responses in the 1st year of life.

D. Nicolae, C. Ober, I. Ostrovnaya, 2005, American journal of human genetics.

Testing clonality of three and more tumors using their loss of heterozygosity profiles

I. Ostrovnaya, 2012, Statistical Applications in Genetics and Molecular Biology.

Growth patterns of survivors of retinoblastoma treated with ophthalmic artery chemosurgery

I. Ostrovnaya, A. Knezevic, Y. Gobin, 2018, PloS one.

Estimating the dose–toxicity curve in completed phase I studies

Alexia Iasonos, Irina Ostrovnaya, I. Ostrovnaya, 2011, Statistics in medicine.

A phase II trial cohort of nivolumab plus ipilimumab in patients (Pts) with recurrent/metastatic salivary gland cancers (R/M SGCs).

I. Ostrovnaya, A. Ho, D. Pfister, 2021 .

An EM algorithm to improve the estimation of the probability of clonal relatedness of pairs of tumors in cancer patients

V. Seshan, C. Begg, I. Ostrovnaya, 2019, BMC Bioinformatics.

When overall survival fails to confirm event-free survival, should the latter be used to set the standard of care?

I. Ostrovnaya, S. Roberts, B. Kushner, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Split-dose cisplatin as an alternative to every-3-week dosing when using cisplatin/gemcitabine to treat advanced urothelial cancer.

I. Ostrovnaya, G. Iyer, D. Bajorin, 2015 .

Adverse pathologic features impact survival outcomes for small renal masses following nephrectomy.

P. Russo, I. Ostrovnaya, S. Tickoo, 2023, Urologic oncology.

Resource-efficient pooled sequencing expands translational impact in solid tumors

M. Berger, Nicole Rusk, P. Russo, 2021, bioRxiv.

Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial

I. Ostrovnaya, N. Katabi, A. Ho, 2023, Nature medicine.

Neoadjuvant atezolizumab (A) with gemcitabine and cisplatin (GC) in patients (pts) with muscle-invasive bladder cancer (MIBC): A multicenter, single-arm, phase 2 trial.

I. Ostrovnaya, G. Iyer, H. Al-Ahmadie, 2021 .

Neoadjuvant nivolumab (N) +/- ipilimumab (I) in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC).

I. Ostrovnaya, G. Iyer, H. Al-Ahmadie, 2022, Journal of Clinical Oncology.

Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma.

S. Gabriel, G. Getz, P. Kantoff, 2014, Cancer discovery.

Pre-operative chemotherapy (ctx) in plasmacytoid urothelial carcinoma (PUC).

I. Ostrovnaya, G. Iyer, H. Al-Ahmadie, 2018 .

Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission.

I. Ostrovnaya, N. Cheung, B. Kushner, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy.

N. Socci, B. Taylor, N. Schultz, 2014, Cancer discovery.

Genome Sequencing Identifies a Basis for Everolimus Sensitivity

C. Sander, N. Socci, B. Taylor, 2012, Science.

Differential NEUROD1, ASCL1, and POU2F3 Expression Defines Molecular Subsets of Bladder Small Cell/Neuroendocrine Carcinoma with Prognostic Implications.

I. Ostrovnaya, S. Tickoo, G. Iyer, 2024, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody

P. Kantoff, J. Boehm, G. Kryukov, 2014 .

A phase II trial cohort of nivolumab plus ipilimumab in patients (Pts) with recurrent/metastatic adenoid cystic carcinoma (R/M ACC).

I. Ostrovnaya, N. Katabi, A. Ho, 2019, Journal of Clinical Oncology.

Surgical outcomes of cytoreductive nephrectomy in patients receiving systemic immunotherapy for advanced renal cell carcinoma.

I. Ostrovnaya, R. Motzer, Chung-Han Lee, 2023, Urologic oncology.

NEXT GENERATION SEQUENCING OF UROTHELIAL BLADDER CANCER: MEMORIAL SLOAN KETTERING CANCER CENTER EXPERIENCE IN 454 PATIENTS: MP54‐04

M. Berger, I. Ostrovnaya, G. Iyer, 2018 .